Dr. Madi R. Madiyalakan, Chief Executive Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email: [email protected], Internet: www.questpharmatech.comCopyright CNW Group 2015
Quest PharmaTech Closes $2,000,000 Private Placement With Hepalink USA
View original source (CNW)Quest PharmaTech Inc. on 6ix
Earlier from Quest PharmaTech
- Quest PharmaTech Closes $1,000,000 Private Placement
- Quest PharmaTech Announces Results from its 2014 AGM
- Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin(TM); Dr. Jacqueline Shan, Creator of COLD FX®, to Assist
- Quest PharmaTech Provides Financial Update
- Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer
Later from Quest PharmaTech
- Quest PharmaTech's Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement with Hepalink USA to Fund Immunotherapy for Treatment of Cancer
- Quest PharmaTech Announces Results from its 2015 AGM
- Quest PharmaTech's Subsidiary, OncoQuest, Signs Agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. to Fund Immunotherapy for Treatment of Cancer in China
- Quest PharmaTech Announces Filing of Restated Audited Financial Statements for the Year Ended January 31, 2016 and for the Quarter Ended April 30, 2016
- /C O R R E C T I O N from Source -- Quest PharmaTech Inc./
Follow Quest PharmaTech into a list and get an email when it puts out news.
Follow Quest PharmaTech